Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients
Sponsor: Changhai Hospital
A observational or N/A phase clinical study on Capecitabine and Colorectal Cancer, this trial is ongoing. The trial is conducted by Changhai Hospital and has accumulated 11 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 6 earlier versions
-
Apr 2019 — Nov 2020 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — Apr 2019 [monthly]
Enrolling By Invitation
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — May 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
-
Feb 2017 — Aug 2017 [monthly]
Enrolling By Invitation NA
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- Shanghai Changzheng Hospital
- Shanghai Minhang Central Hospital
- The 97 Hospital of chinese PLA
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Xuzhou Medical University
For direct contact, visit the study record on ClinicalTrials.gov .